STOCK TITAN

Inspira Technologies Oxy Bhn Ltd - IINN STOCK NEWS

Welcome to our dedicated page for Inspira Technologies Oxy Bhn news (Ticker: IINN), a resource for investors and traders seeking the latest updates and insights on Inspira Technologies Oxy Bhn stock.

Overview

Inspira Technologies Oxy BHN Ltd (IINN) is a specialty medical device company committed to transforming the landscape of respiratory care. With a focus on life support and respiratory treatment, the company has developed a breakthrough Augmented Respiration Technology (INSPIRA ART) that provides a non-invasive alternative to traditional mechanical ventilation. The technology is designed to elevate oxygen saturation and reduce carbon dioxide levels in patients, addressing a critical need in the management of acute respiratory failure.

Core Technology and Innovation

The hallmark of Inspira Technologies is its pioneering approach to respiratory support. Its INSPIRA ART system employs advanced principles of extracorporeal oxygenation, substituting the direct mechanical intervention of traditional ventilators with a sophisticated intravascular apparatus. This device promises to stabilize oxygen levels rapidly without the complications that are often associated with mechanical ventilation, thereby offering patients the possibility of remaining awake during treatment.

Complementing the INSPIRA ART is the company’s innovative HYLA blood sensor technology. This AI-powered continuous monitoring system provides real-time data on a patient’s blood oxygenation and carbon dioxide levels, allowing healthcare professionals immediate access to critical parameters. The integration of HYLA enhances the utility of the INSPIRA ART, offering continuous feedback and contributing to a more informed clinical decision-making process.

Market Significance and Competitive Position

Inspira Technologies operates in a competitive yet rapidly evolving segment of the medical devices market. The problems associated with invasive mechanical ventilation, such as high treatment costs, complications, and a heavy burden on ICU resources, position the company’s offerings as potentially disruptive in a market that handles millions of cases of acute respiratory failure annually. By addressing both the mechanical and monitoring aspects of respiratory support through its dual technologies, the company is carving out a unique position that resonates with healthcare providers who seek safer, more efficient, and patient-centric solutions.

Regulatory Achievements and Clinical Insights

The company has achieved significant regulatory milestones, obtaining clearance for its INSPIRA ART systems in key procedures such as Cardiopulmonary Bypass. These clearances underscore the robustness and safety of its design. Additionally, the clinical evaluations of its HYLA blood sensor technology at internationally recognized medical institutions demonstrate the company’s commitment to aligning innovation with established clinical protocols and standards.

Product Portfolio and Operational Excellence

Beyond its flagship INSPIRA ART system and the supporting HYLA sensor, Inspira Technologies is actively developing a robust pipeline of products aimed at addressing various facets of respiratory support and blood monitoring. The company’s research, development, manufacturing, and marketing operations are tailored to meet the rigorous demands of modern critical care, emphasizing ease of use, rapid response, and integration with existing hospital systems.

Strategic Collaborations and Global Reach

Recognizing the global need for improved respiratory care, Inspira Technologies has engaged in strategic collaborations with leading hospitals and distributors across multiple regions including North America, Europe, and Asia Pacific. These partnerships not only validate the technological merits of the company’s products but also help penetrate diverse healthcare markets that continue to rely heavily on traditional ventilation methods.

Commitment to Quality and Clinical Impact

The company’s approach blends robust technological innovation with a keen understanding of clinical challenges. By focusing on continuous innovation through rigorous trial evaluations, adherence to regulatory standards, and integration of AI-powered analytics, Inspira Technologies is dedicated to enhancing patient outcomes in critical care settings while alleviating operational burdens on healthcare providers.

Conclusion

Inspira Technologies Oxy BHN Ltd represents a thoughtful blend of technical innovation and clinical pragmatism. It stands out for its effort to revolutionize respiratory support through cutting-edge non-invasive technologies that offer an alternative to conventional mechanical ventilation. With a comprehensive business model centered on enhancing both patient care and operational efficiency in critical care environments, the company is well-positioned in its sector as healthcare institutions increasingly seek solutions that combine safety, rapid responsiveness, and sustained reliability.

Rhea-AI Summary
Inspira Technologies OXY B.H.N. Ltd. (Nasdaq: IINN) is pleased to announce the appointment of Dr. Dan Gorfil to its medical advisory board. Dr. Gorfil, a distinguished specialist in cardiac surgery and intensive care medicine, is expected to significantly contribute to the deployment of the INSPIRA™ ART100. U.S. Food and Drug Administration (FDA) approval is expected in the first half of 2024. The company is leading the way in transforming life-support care, with innovative solutions that pave the way for direct blood oxygenation and AI-driven monitoring systems, potentially enhancing patient outcomes and streamlining hospital operations.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.9%
Tags
management clinical trial
-
Rhea-AI Summary
Inspira Technologies OXY B.H.N. Ltd. (Nasdaq: IINN) (Nasdaq: IINNW) announces partnership with Ennocure MedTech Ltd. to develop bio-electronic technology for bloodstream infection prevention. The company aims to revolutionize life support technology by integrating oxygenation and infection prevention solutions, potentially improving patient outcomes and reducing healthcare costs.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.9%
Tags
none
-
Rhea-AI Summary
Inspira Technologies OXY B.H.N. Ltd. (Nasdaq: IINN) Announces Q3 Financial Results and Progress in Novel Oxygenation Technology Development
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2%
Tags
Rhea-AI Summary
Inspira Technologies has received a grant from the Israeli Innovation Authority for its VORTX Disposable Blood Oxygenation Technology. The VORTX is designed to oxygenate blood and remove carbon dioxide, addressing a $4 billion perfusion disposable market in the medical devices sector. The grant covers 40% of the first-year approved budget of $1 million.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.79%
Tags
none
-
Rhea-AI Summary
Inspira Technologies receives additional patent for respiratory medical device, INSPIRA ART500
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.63%
Tags
none
-
Rhea-AI Summary
Inspira Technologies terminates its at-the-market equity offering program. Operations unaffected by ongoing war.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.15%
Tags
none
Rhea-AI Summary
Inspira Technologies signs distribution agreement with CIO MED GROUP, potentially generating $28 million in recurring revenues
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.61%
Tags
none
-
Rhea-AI Summary
Inspira Technologies unveils INSPIRA ART line at ELSO Conference, including INSPIRA ART100 and ART500 devices. INSPIRA ART500 offers potential breakthrough treatment for severe breathing problems. INSPIRA ART100 estimated to receive FDA clearance in H1 2024. Collaboration with Perfusion Solution for U.S. availability.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.15%
Tags
none
-
Rhea-AI Summary
Inspira Technologies submits INSPIRA ART 100 to FDA, expects clearance in first half of 2024
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.82%
Tags
none
Rhea-AI Summary
Inspira Technologies OXY B.H.N. Ltd. announces financial results for Q2 2023. The company had $8.9 million in cash, cash equivalents, and short-term bank deposits as of June 30, 2023. The INSPIRA ART100 is planned for submission to the FDA for clearance. The INSPIRA ART500 is being developed with integrated AI and blood sensor technology. The net loss for the six months ended June 30, 2023, was $5.9 million.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.6%
Tags

FAQ

What is the current stock price of Inspira Technologies Oxy Bhn (IINN)?

The current stock price of Inspira Technologies Oxy Bhn (IINN) is $0.6414 as of April 1, 2025.

What is the market cap of Inspira Technologies Oxy Bhn (IINN)?

The market cap of Inspira Technologies Oxy Bhn (IINN) is approximately 17.0M.

What is the core business of Inspira Technologies Oxy BHN Ltd?

Inspira Technologies focuses on developing innovative respiratory support and life support technologies that serve as alternatives to invasive mechanical ventilation.

How does the INSPIRA ART system differ from traditional mechanical ventilators?

The INSPIRA ART system is designed to enhance oxygen levels and remove carbon dioxide using an intravascular approach, potentially reducing complications and allowing patients to remain awake during treatment.

What role does the HYLA blood sensor technology play in Inspira's product portfolio?

The HYLA blood sensor provides real-time, continuous monitoring of blood parameters, enabling immediate clinical feedback and supporting informed decisions during respiratory treatment.

Which market segments does Inspira Technologies serve?

The company targets the respiratory care and life support markets globally, with applications in intensive care units, operating rooms, and other critical care settings.

What regulatory achievements has Inspira Technologies accomplished?

Inspira Technologies has obtained key regulatory clearances, such as FDA 510(k) clearance for its INSPIRA ART systems in procedures like Cardiopulmonary Bypass, underscoring its commitment to safety and clinical efficacy.

How do Inspira Technologies' solutions benefit healthcare providers?

By offering non-invasive respiratory support and continuous blood monitoring, the company’s technologies can improve patient care, reduce the complications associated with traditional ventilation, and provide rapid clinical information.

What distinguishes Inspira Technologies within the competitive medical device market?

The company combines breakthrough respiratory support technology with advanced, AI-powered blood monitoring, positioning it uniquely against traditional ventilation methods and addressing key clinical challenges.
Inspira Technologies Oxy Bhn Ltd

Nasdaq:IINN

IINN Rankings

IINN Stock Data

17.00M
24.59M
4.01%
4.55%
0.61%
Medical Devices
Healthcare
Link
Israel
Ra'anana